pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
REGENERON PHARMACEUTICALS · news · pharmadog
← back to REGENERON PHARMACEUTICALS
News mentioning REGENERON PHARMACEUTICALS
27
stories
18h
Regeneron to challenge Ipsen as FDA clears bone disease drug
biopharma dive
21h
STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
stat
1d
STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approval
stat
1d
11 companies hiring in New Jersey
biospace
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
3d
EyePoint plummets on pivotal data for main drug
biopharma dive
3d
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
biospace
3d
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
fiercebiotech
8d
7 companies hiring in North Carolina now
biospace
10d
Regeneron backs $75M series A for antibody upstart Infinimmune
fiercebiotech
15d
The top 12 companies hiring in biopharma now
biospace
15d
A COPD drug from China draws $115M in venture funding
biopharma dive
20d
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
21d
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
biospace
22d
7 companies hiring in New York now
biospace
29d
6 companies hiring in Cambridge now
biospace
Jul 10, 26
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
biopharma dive
Jun 30, 26
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
biopharma dive
Jun 29, 26
FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing
fda press
Jun 11, 26
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
biopharma dive
Jun 10, 26
Parabilis sets a record with a $670M biotech IPO
biopharma dive
Jun 3, 26
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
biopharma dive
May 18, 26
Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3
endpoints
May 6, 26
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
onclive
May 6, 26
STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field
stat
Apr 28, 26
Coultreon banks $125M to support testing of former Galapagos immune drug
biopharma dive
